Stockscreener 앱 받기
1.38
1.47%
0.02
시간 외 거래:
1.40
0.02
+1.45%
전일 마감가:
$1.36
열려 있는:
$1.42
하루 거래량:
5.09M
Relative Volume:
1.01
시가총액:
$431.00M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-5.1111
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+15.00%
1개월 성능:
+15.97%
6개월 성능:
+22.12%
1년 성능:
+60.95%
1일 변동 폭
$1.37
$1.483
1주일 범위
$1.19
$1.483
52주 변동 폭
$0.515
$1.90
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.38 | 424.76M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
How The Latest Analyst Shifts Are Reshaping Ocugen’s Story and Valuation - Yahoo Finance
Ocugen Inc Stock Analysis and ForecastSector Rotation Strategies & Free Rapid Growing Investment Returns - earlytimes.in
Growth Recap: Is Ocugen Inc stock supported by strong cash flowsJuly 2025 Review & Stepwise Trade Execution Plans - moha.gov.vn
Institutional Giant Janus Henderson Makes Major Bet on Ocugen - AD HOC NEWS
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Ocugen I - GuruFocus
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen CEO’s Keynote Address Meets Heightened Market Skepticism - Ad-hoc-news.de
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen, Inc. Chairman and CEO Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit - Quiver Quantitative
Major Fund Manager Acquires Significant Stake in Ocugen Amid Share Price Weakness - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. Stock Falls Friday, Underperforms Market - 富途牛牛
Institutional Backing and Geopolitical Tailwinds for Ocugen - AD HOC NEWS
Ocugen Secures Validating Partnership for Gene Therapy Platform - AD HOC NEWS
How robust is Ocugen Inc. (2H51) stock financial positionMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
Why institutional investors increase stakes in Ocugen Inc. (2H51) stockJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
How Ocugen Inc. (2H51) stock compares with tech leadersEarnings Growth Summary & Weekly Hot Stock Watchlists - Newser
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Is Ocugen Inc. (2H51) stock resilient in recession scenarios2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
Why Ocugen Inc. stock appeals to analystsWeekly Trade Analysis & Risk Controlled Swing Alerts - Newser
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference - MSN
Can Ocugen Inc. (2H51) stock deliver consistent EPS growth2025 Volatility Report & Safe Capital Growth Stock Tips - Newser
Is Ocugen Inc. (2H51) stock good for long term investingRisk Management & Free Community Consensus Stock Picks - Newser
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments - Yahoo Finance
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MSN
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen Inc 2H51 Stock Analysis and ForecastEarnings Surprise Analysis & Low Cost Capital Trading - earlytimes.in
Ocugen, Inc.Common Stock (NQ: OCGN - Markets Financial Content
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Stock Price and Chart — NASDAQ:OCGN - TradingView
Ocugen, Inc. (OCGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Ocugen Inc. (2H51) stock outperform energy sector in 20252025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Is Ocugen Inc. stock a defensive play in 20252025 Dividend Review & Real-Time Market Trend Scan - newser.com
Why retail investors favor Ocugen Inc. stockWeekly Trend Summary & AI Forecasted Stock Moves - newser.com
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - Ocugen
How Ocugen Inc. (2H51) stock trades after rate cuts2025 Price Action Summary & Verified Technical Signals - newser.com
Ocugen CEO to Present at NobleCon21-Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - The Manila Times
Ocugen CEO Dr. Shankar Musunuri to Present at NobleCon21 Conference on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth ... - Herald and News
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ - GlobeNewswire
Why Ocugen Inc. (2H51) stock could outperform next yearPortfolio Value Summary & AI Optimized Trading Strategy Guides - newser.com
Is Ocugen Inc. showing signs of accumulationSwing Trade & Weekly Top Performers Watchlists - newser.com
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):